These include antibodies against programmed death-1 (PD-1), PD ligand-1, (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4).1 ICI improve outcomes in patients with a variety of cancers, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC), both in metastatic and early-stage settings.1-8 Immune-related adverse events (irAEs) can affect any organ with higher incidences after combination.1,9,10 Neurological irAEs (nirAEs) affect 1.5% of patients treated with ICI with serious events occurring in 0.2%-0.8%. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.